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When we expose ourselves to natural sunlight this is 
mainly visible light; ultraviolet radiation (UVR) is only a 
small component of natural daylight (Figure 1). Of the 
UVR, most will be UVA with less than 5% being UVB. 
Ultraviolet exposure will depend on the time of the 
year. For example in northern Europe we will not 
receive any UVB exposure in winter and relatively less 
UVA on sunny winter days than we would be exposed 
to in the summer. 
The term ‘photosensitivity’ is used to describe the acute 
reaction of skin to UVR. This may fall within normal 
population responses and individuals may be categorised 
according to their sensitivity to sunburn and their ability 
to tan using the Fitzpatrick skin phototype classification.1 
Photosensitivity is considered abnormal if the reaction 
of skin to UVR is either quantitatively or qualitatively 
outwith that of the normal population. Thus, if an 
individual has a lowered susceptibility to developing a 
sunburn-like reaction after minimal sun exposure, or 
develops a rash after sun exposure, this would be 
considered to be abnormal. 
Photosensitivity diseases are a heterogeneous group of 
conditions (Table 1) and detailed clinical assessment is 
vital in order to elicit a history of photosensitivity and 
to provide clues to the characteristics of the reaction 
and thus the possible diagnosis. The age of onset of the 
condition is important as there are some disorders such 
as actinic prurigo, hydroa vacciniforme and erythropoietic 
protoporphyria which tend to present in childhood and 
others, such as chronic actinic dermatitis, which usually 
occur in later life. It is essential to determine the 
characteristics of the type of ultraviolet or visible light 
exposure which is required to trigger the abnormal 
photosensitivity. Thus, establishing whether the condition 
is triggered throughout the year or just in spring and 
summer and whether it is only direct sunlight 
exposure, window glass transmitted light and/or 
sunbed exposure that will trigger the problem are key 
factors. Disorders in which UVA and visible light 
photosensitivity feature are more likely to be 
associated with perennial symptoms as opposed to 
disorders restricted particularly to UVB and the 
shorter UVA wavelengths which will often be more 
common in spring and summer. Window glass absorbs 
UVB and allows transmission of UVA therefore if 
photosensitivity is triggered with light through 
window glass this implies that UVA and/or visible 
wavelengths are triggering the problem.
It is also important to establish the time required to 
produce the photosensitivity reaction and the lag period 
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Figure 1 Emission spectrum of solar exposure 
demonstrating the relative proportions of UVR and visible 
light. From Frain-Bell W. Cutaneous Photobiology. Oxford 
University Press: Oxford; 1985. p.136–9
until this occurs. For example, polymorphic light eruption 
typically requires a few hours of exposure to trigger an 
itchy rash which may not develop until later that day or 
the following day and will last for a few days before 
resolution. In contrast, solar urticaria will usually be 
triggered within minutes of exposure at any time of the 
year and lesions will resolve within an hour or two. If 
clothing is not protective and the patient still develops 
the rash through lightly woven clothing then this implies 
that UVA and/or visible light are implicated in triggering 
the photosensitivity. The presence of hardening (reduced 
sensitivity on habitually exposed sites such as face and 
back of hands), is much more common, for example in 
polymorphic light eruption, than in some of the other 
photosensitive conditions, such as solar urticaria or 
chronic actinic dermatitis. 
Symptoms are informative and anyone with skin pain on 
sun exposure should have porphyria excluded as this 
raises suspicion of a cutaneous porphyria. Itching is 
usually more prevalent in many of the other disorders, 
such as polymorphic light eruption. A fundamental part 
of history taking is a detailed drug history as many drugs 
may cause phototoxicity through non-immunological 
phototoxic mechanisms. These include antibiotics (e.g. 
fluoroquinolones and doxycycline), diuretics (e.g. 
thiazides), non-steroidal anti-inflammatory drugs (oral 
and topical), quinine, phenothiazines, calcium antagonists, 
amiodarone or ingested St John’s wort. It is essential to 
pinpoint this from the history as (if this is the diagnosis) 
once the culprit drug is stopped the photosensitivity 
should resolve. Family history may be relevant in some 
of the photosensitive conditions such as in actinic 
prurigo, with 50% of Caucasian patients having a positive 
family history for the disease, rising to 75% in South 
America. It is important to discuss and obtain details of 
the patient’s occupation as this may well be relevant, for 
example in the case of photocontact allergy to specific 
photoallergens such as occupational non-steroidal anti-
inflammatory drug exposure.2 Likewise, recreational 
exposure may be important as in the case of 
phytophotodermatitis or ‘strimmer’s’ dermatitis. There is 
emerging evidence3–6 to demonstrate that chronic and, in 
particular severe photosensitivity, has a significant 
adverse impact on quality of life. This is important to be 
aware of and relatively high levels of depression and 
anxiety are reported in this group of patients. 
On examination, there are usually clues to the presence of 
a photodistributed rash, with prominent involvement of 
photoexposed sites on the head and neck including the 
forehead, nose, chin, sternocleidomastoid and mastoid 
areas, balding head, top of ears and back of neck. Typically 
these may be sparing around the eyes and in the shadows 
cast by the ears (Wilkinson’s triangle), sideburns, lower lip 
and under the chin. Characteristically, in airborne contact 
dermatitis, the upper eyelids are involved and in 
photosensitivity these are spared. Likewise with airborne 
contact dermatitis, the back of the neck is typically spared 
whereas in photosensitivity this is a commonly affected site. 
The extensor surfaces of arms and forearms and back of 
hands may be most prominently affected and on the lower 
limbs photosensitivity will typically affect the extensor 
surfaces, particularly the tops of thighs and tops of feet.
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Photoaggravated
Figure 2 Subtle vacciniforme scarring on the cheek of a 
child with hydroa vacciniforme
Figure 3 Leucomelanoderma arising in a patient with 
skin phototype V with chronic actinic dermatitis 
Ascertaining the nature of a rash is important: papules 
and vesicles would lead to consideration of, for 
example, polymorphic light eruption or actinic prurigo, 
or if vesicle fluid is haemorrhagic then hydroa 
vacciniforme. Vacciniforme scarring, which may be 
subtle (Figure 2), should be looked for as it does make 
a diagnosis of hydroa vacciniforme more likely. If the 
rash is urticated in nature then this is suggestive of 
either primary or secondary solar urticaria, and if there 
is erythema and later desquamation then the possibility 
of drug phototoxicity should be considered. The 
presence of photoexposed site dermatitis should lead 
to consideration of a diagnosis of chronic actinic 
dermatitis, photocontact allergic dermatitis or the 
main differential diagnosis of airborne contact allergic 
dermatitis. Pigmentary changes such as leucomelano-
derma commonly occur with certain drug photo-
sensitisers such as quinine or thiazides but can also 
occur in chronic actinic dermatitis (Figure 3). Skin 
fragility, scarring and milia should always alert suspicions 
of a cutaneous porphyria. 
If a patient is suspected to have a photosensitivity 
disorder then they should be referred for investigation 
to a specialist photodiagnostic unit. The objectives of 
investigation are to define the nature of the 
photosensitivity and establish a firm diagnosis (Table 2). 
The mainstay investigation is monochromator 
phototesting which is the use of a xenon arc source 
which is filtered to allow delivery of narrow wavebands 
of light across the solar spectrum in order to establish 
erythemal responses and compare these with a normal 
population range (Figure 4). The minimal erythema dose 
(MED) is the threshold dose of irradiation required to 
cause just perceptible erythema. This is the objective 
endpoint usually measured at 24 hours after 
monochromator phototesting and is used to determine 
most cases of abnormal photosensitivity. In solar urticaria 
where immediate photosensitivity is the problem, the 
minimal urticarial dose (MUD), the dose of irradiation 
required to elicit just detectable urticaria, is used as the 
main outcome measure. Other investigations will often 
include broadband provocation testing usually with UVA 
and patch or photopatch testing. The latter is undertaken 
to sunscreens and topical non-steroidal anti-
inflammatories and is used to investigate possible 
photocontact allergy to these drugs and chemicals.7 
Screening for lupus , the cutaneous porphyrias or other 
rarer photosensitivity diseases may be required (Table 3).
With the introduction of environmentally friendly low 
energy compact fluorescent lighting, these sources now 
emit more into the UV part of the spectrum and can 
pose a risk for severely photosensitive patients such as 
those with solar urticaria, chronic actinic dermatitis or 
lupus.8-10 It is now possible to undertake phototesting 









Figure 4 Monochromator phototesting. (Left) Phototesting with patient sitting comfortably. Filtered xenon arc source (on 
trolley) is coupled to a fibre-optic light guide. (Right) Irradiation undertaken at test sites on clinically normal appearing back 
skin and delivered via fibre-optic light guide
Table 3 investigations that may be used in a 











Table 2 Objectives of investigation
•	 To establish if the patient is abnormally photosensitive
•	 If so, to determine the action spectrum and degree of 
abnormal photosensitivity 
•	 To determine a firm diagnosis
with these compact fluorescent light sources and this 
can be helpful in providing information and advice for 
patients regarding lighting choices, notably the use of 
double enveloped compact fluorescent lamps or LEDs 
(Table 3). MED testing to lamps that can be used to treat 
photosensitive disorders, through induction of 
desensitisation and tolerance, are also often undertaken 
and MED testing is an essential safety measure in order 
to pick up any abnormal photosensitivity reactions 
before a treatment course of phototherapy (Table 3). 
Patients referred for investigation often have many 
investigations done and it is important to look at the 
clinical relevance of any investigation findings. 
Furthermore, investigations may be negative and yet the 
patient may still have exacerbation of their condition by 
light such as in the photoaggravated skin diseases, for 
example rosacea or seborrhoeic dermatitis. 
Idiopathic photodermatoses include the majority of 
abnormal cutaneous reactions to sunlight (Table 1) and 
this is explained on the basis of the prevalence of 
polymorphic light eruption in 18% of European 
populations.11 A further category of abnormal 
photosensitivity diseases is those induced by drugs and 
chemicals. These include endogenous chemicals in the 
porphyrias, exogenous systemic or topical drugs and 
chemicals (for example with systemic quinine, thiazides, 
fluoroquinolones, doxycycline or amiodarone 
phototoxicity) or topical photocontact allergy to non-
steroidal anti-inflammatories applied directly to the 
skin or sunscreen chemicals. Some of the more 
recently introduced drugs, such as the BRAF inhibitor 
vemurafenib, used for metastatic melanoma (Figure 5), 
voriconazole, pirfenidone for lung fibrosis and anti-
hepatitis C agents have also been associated with 
photosensitivity. Most drug photosensitivity is mediated 
by UVA and visible wavelengths. 
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Figure 6 Abnormal pigmentary change (lentigines and 
hypopigmented macules), dysplastic changes and scarring in 
a patient of skin phototype V with xeroderma pigmentosum. 
The purple marker pen demonstrates a site to be biopsied. 
(c/o Dr Hiva Fassihi, Clinical Lead for the National XP 
Service, Guy’s & St Thomas’ Hospital, London)
Figure 5 Vemurafenib phototoxicity. Note prominent involvement of photo-exposed sites on back of hands.  Sunlight 
(UVA) exposure a few days earlier resulted in a blistering phototoxic reaction
Photogenodermatoses are a rare group of diseases in 
which photosensitivity is a manifestation and key aspect 
of the disease. The best known is xeroderma pigmentosum 
(Figure 6) which is a rare group of autosomal recessive 
conditions in which DNA excision repair pathways or 
post replication repair pathways are abnormal. Patients 
develop markedly accelerated photoaging and non-
melanoma skin cancers and many will also have severe 
delayed abnormal photosensitivity. Photoaggravated 
photodermatoses constitute another relatively large 
group of conditions which are exacerbated but not 
caused by light and it may well be that the infra-red 
component of sunlight is part of the trigger. 
The key points to stress are that it is important to have 
a low threshold for thinking about photosensitivity on 
clinical assessment of a patient and that there are usually 
clues in the patient’s history and examination findings. It 
is also advisable to have a low threshold when referring 
for investigation, for example in a patient with 
longstanding atopic dermatitis in whom there may be a 
history of change in the seasonal pattern of their disease. 
They may have problems in the summer more than in 
the winter or they may have sites of involvement such as 
on the head and neck for the first time and it may well 
be that this patient has developed chronic actinic 
dermatitis. In this setting, particularly if the narrowband 
UVB MED that is undertaken prior to phototherapy is 
abnormal, the patient should be referred for 
monochromator phototesting to exclude chronic actinic 
dermatitis. A range of investigations is available – not all 
of these will be used in all patients but will be adapted 
according to the clinical presentation, for example drug-
induced photosensitivity, lupus or cutaneous porphyrias.
The longer term risks of chronic photosensitivity are 
not well understood although in the idiopathic 
photodermatoses there is no evidence of any increased 
risk of skin cancer or other malignancies. Indeed, in 
polymorphic light eruption there appears to be a 
reduced lifetime risk of skin cancer even allowing for the 
confounding factor of photoprotection.12 The association 
between drug phototoxicity and possible skin cancer 
risk is becoming clearer with the use of some drugs 
which seem to be associated with an increased risk of 
skin cancer, such as the phototoxic fluoroquinolones, 
voriconazole and the BRAF inhibitors, notably 
vemurafenib. The mechanisms underlying any link 
between drug phototoxicity and photocarcinogenesis, 
or potential ocular or systemic toxicity, are not fully 
clarified and this area requires further investigation.13
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